• Bay 11-7821 in NF-κB Assay Workflows

  2026-08-18

  Bay 11-7821, also known as BAY 11-7082, is a practical IKK/NF-κB pathway probe for separating inflammatory transcription from apoptosis and proliferation phenotypes. This guide connects dose-controlled cell assays with macrophage HMGB1 research, while emphasizing solubility, timing, and interpretation limits.

• Adefovir Workflows for HBV and OAT1 Research

  2026-08-18

  Build reproducible Adefovir assays for HBV polymerase inhibition, viral replication studies, and OAT1 transporter phenotyping. This workflow separates antiviral exposure from renal-transport measurements while adapting structural-biology quality controls from a DDX3 crystallography study.

• Ibrutinib: Mechanism-to-Readout Research Guide

  2026-08-17

  Ibrutinib (PCI-32765) is a covalent BTK inhibitor for connecting B-cell receptor signaling inhibition with interpretable cellular phenotypes. This guide emphasizes assay architecture, controls, solvent handling, and lessons from an orthogonal disease-model study.

• From T7 Transcription to Smarter RNA Delivery

  2026-08-17

  T7 RNA Polymerase is more than a high-yield transcription reagent: it is the upstream control point for RNA quality, template reproducibility, and translational decision-making. This thought-leadership article connects defined RNA synthesis with recent evidence that LNP trafficking and endosomal escape—not cellular uptake alone—shape functional delivery.

• Nintedanib (BIBF 1120) Assay Guide

  2026-08-16

  A scenario-based guide to using Nintedanib (BIBF 1120), SKU A8252, in cell viability, proliferation, and cytotoxicity experiments. It connects target potency, DMSO handling, assay controls, ATRX-informed interpretation, and practical supplier selection to improve experimental consistency.

• Gingerenone A Reverses Sunitinib Resistance in RCC

  2026-08-15

  The January 2026 study identifies gingerenone A as an inhibitor of LDHA-driven glycolysis in renal cell carcinoma and links this metabolic effect to disruption of HIF-1α/VEGFA/VEGFR2 signaling. Across biochemical, cellular, and animal models, gingerenone A improved sunitinib activity and restored drug responsiveness in resistant RCC models, supporting metabolism-directed combination therapy while leaving important translational questions unresolved.

• WP1066 for JAK2/STAT3 Signaling Research

  2026-08-15

  WP1066 provides a cell-permeable way to interrogate JAK2/STAT3 signaling in cancer cell proliferation, AML models, and macrophage-centered regeneration studies. This guide connects dose–response assays with scaffold-based pathway validation and practical troubleshooting.

• Doxorubicin Hydrochloride: Assay Workflows

  2026-08-14

  Build reproducible cancer cytotoxicity and cardiotoxicity experiments with Doxorubicin hydrochloride, from dose–time matrices to mechanism-focused validation. This workflow connects DNA damage and apoptosis readouts with the emerging ATF4–H2S antioxidant axis.

• Arrb2, 6-ketoLCA, and Hepatic IRI

  2026-08-14

  This study identifies a hepatocyte Arrb2–6-ketoLCA–M2 macrophage axis that limits hepatic ischemia–reperfusion injury. By combining transplant-associated clinical samples, hepatocyte-targeted mouse models, metabolite profiling, and hypoxia–reoxygenation experiments, the work connects hepatocyte signaling with macrophage-mediated inflammatory resolution.

• IAM LC vs LEKC for Pulmonary Drug Permeability

  2026-08-13

  This Journal of Chromatography A study provides a direct comparison of immobilised artificial membrane liquid chromatography and liposome electrokinetic capillary chromatography for modeling drug–membrane partitioning and pulmonary permeability. LEKC more closely reflected apparent lung permeability for the tested compounds, whereas IAM LC offered broader compound coverage, simpler implementation, and stronger suitability for high-throughput screening.

• Bacitracin (B1670): Protocol and QC Guide

  2026-08-13

  Bacitracin (B1670) provides a peptide antibiotic for controlled antibacterial research involving bacterial cell wall and peptidoglycan synthesis. This guide covers solvent selection, storage, assay controls, and troubleshooting; the material is for scientific research only and must not be used for diagnostic or medical applications.

• Bufalin Targets STK33 in Triple-Negative Breast Cancer

  2026-08-12

  A 2025 Advanced Science study identifies serine/threonine kinase 33 (STK33) as a direct Bufalin-binding protein and a degradation-sensitive driver of triple-negative breast cancer. By combining target discovery, biophysical validation, genetic perturbation, animal models, and patient-derived organoids, the work provides a mechanistic framework for evaluating Bufalin-centered TNBC research workflows.

• DZNep Workflows for Epigenetic Cancer Research

  2026-08-12

  Build reproducible DZNep experiments around SAHH inhibition, EZH2 depletion, apoptosis, and tumor-sphere assays. This guide links concentration planning and troubleshooting to AML, hepatocellular carcinoma, metabolic models, and context-aware cancer assay design.

• Spatial Proteomics Maps PD-L1–IL-6 Crosstalk in PSC

  2026-08-11

  Orlandi and colleagues combine spatial proteomics with cell–cell cross-talk analysis to examine how PD-L1 and IL-6 are organized at the epithelial–immune interface in human primary sclerosing cholangitis. The study provides a spatial framework for interpreting coupled immune-checkpoint and inflammatory signaling, while also clarifying why localization-based evidence should precede causal or therapeutic claims.

• WP1066: JAK2/STAT3 Inhibitor Workflows

  2026-08-10

  WP1066 is a cell-permeable JAK2/STAT3 inhibitor for connecting pathway perturbation with measurable changes in cancer-cell growth, apoptosis, and immune-cell behavior. This guide translates its use into practical dose-response, signaling, conditioned-medium, and macrophage-focused workflows while clarifying what the bone-regeneration literature does—and does not—prove.

444 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page